### AWARD NUMBER: W81XWH-15-2-0026

TITLE: Clinical Evaluation of Decellularized Nerve Allograft with Autologous Bone Marrow Stem Cells to Improve Peripheral Nerve Repair and Functional Outcomes

PRINCIPAL INVESTIGATOR: Leon Nesti, MD, PhD, LTC, MC, USA

CONTRACTING ORGANIZATION: Henry M. Jackson Foundation 6720 A Rockledge Dr, Suite 100 Bethesda, MD 20817

**REPORT DATE: JULY 2019** 

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE						
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintainini data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for rectibility burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 222 4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a creation of UMB new response.     1. REPORT DATE   2. REPORT TYPE						
data needed, and completing a	and reviewing this collection of ir	formation. Send comments rega	arding this burden estimate or an	y other aspect of this co	ellection of information, including suggestions for reducing	
valid OMB control number. PL	EASE DO NOT RETURN YOU	R FORM TO THE ABOVE ADDR	RESS.	tor raining to comply with		
	2	2. REPORT TYPE		-		
JULY 2019	1	Annual			July 2018 - 30 June 2019	
4. TITLE AND SUBTIT	LE Clinical Evaluation	of Decellularized Nerve	Allograft with	5a.	CONTRACT NUMBER	
Autologous Bone Marrow Stem Cells to Improve Peripheral Nerve Re			epair and Functional		GRANT NUMBER 1XWH-15-2-0026	
Outcomes				_		
Cutoonioo				əc.	PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Leon Nesti, LTC, M	C. USA			5d.	PROJECT NUMBER	
				5e.	TASK NUMBER	
			5f. \	WORK UNIT NUMBER		
E-Mail: leon.nesti	2)usuhs.edu	AND ADDDD00/50				
7. PERFORMING ORG	SANIZATION NAME(S)	AND ADDRESS(ES)			ERFORMING ORGANIZATION REPORT	
	son Foundation lge Dr, Suite 1 20817			itary		
		Bethesda,	MD 20889			
9. SPONSORING / MC	NITORING AGENCY N	AME(S) AND ADDRES		10.	SPONSOR/MONITOR'S ACRONYM(S)	
			-()			
-	Research and Ma	teriel Command				
Fort Detrick, Maryl	and 21702-5012				SPONSOR/MONITOR'S REPORT	
					NUMBER(S)	
Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT						
decellularized proce stem cells (BMSC) thas been shown to h The current standard for repairs are limite nerve graft mitigates scaffold with the pat wound-healing envir	ssed peripheral nerve for the reconstruction ave an established sa l of care for nerve inj ed, and when faced w s concerns of donor si cient's own BMSCs n ronment. The propose	allograft scaffold (Av of mixed peripheral r fety record. Avance h ury, the autograft, has ith severe trauma thes te morbidity, decrease hay allow for point of ed use of an existing c	vance  R Nerve Graft, herve gaps between 3 as been used in more significant limitation e donor sites are not v es surgical time and h care treatment with th	AxoGen, Alach and 7 cm in leng than 10,000 surg s: the source and viable due to cor as substantially ne potential to en- e scaffold with a	ments of a commercially available nua FL) with autologous bone marrow gth. Each treatment separately geries without a reported adverse event. d quantities of autologous tissue needed neurrent injury. Use of a decellularized equivalent outcomes. Augmenting the nhance the regenerative ability of the an autologous stem cell transplant, both type of approach.	
15. SUBJECT TERMS						
Avance nerve graft, autologous bone marrow stem cells (BMSC), nerve autograft, peripheral						
nerve repair						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC	
a. REPORT	b. ABSTRACT	c. THIS PAGE	1		19b. TELEPHONE NUMBER (include area	
			Unclassified	5	code)	
Unclassified	Unclassified	Unclassified		5		

Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

## Table of Contents

### Page

1. Introduction	2
2. Keywords	2
3. Accomplishments	.3
4. Impact	
5. Changes/Problems	.4
6. Products	.4
7. Participants & Other Collaborating Organizations	.4
8. Special Reporting Requirements	.4
9. Appendices	.4

## **Introduction**

The current award is a phase I safety study (n=12) evaluation of the synergistic effect of the cotreatments of a commercially available decellularized processed peripheral nerve allograft scaffold (Avance ® Nerve Graft, AxoGen, Alachua FL) with autologous bone marrow stem cells (BMSC) for the reconstruction of mixed peripheral nerve gaps between 3 and 7 cm in length. Each treatment separately has been shown to have an established safety record. Avance has been used in more than 10,000 surgeries without a reported adverse event.

The current standard of care for nerve injury, the autograft, has significant limitations: the source and quantities of autologous tissue needed for repairs are limited, and when faced with severe trauma these donor sites are not viable due to concurrent injury.

Use of a decellularized nerve graft mitigates concerns of donor site morbidity, decreases surgical time and has substantially equivalent outcomes. Augmenting the scaffold with the patient's own BMSCs may allow for point of care treatment with the potential to enhance the regenerative ability of the wound-healing environment. The proposed use of an existing commercially available scaffold with an autologous stem cell transplant, both with proven safety records, would establish a safety profile and provide a proof of principle for this type of approach.

### **Keywords**

Avance® nerve graft, autologous bone marrow stem cells (BMSC), nerve autograft, peripheral nerve repair

### **Accomplishments**

The study team at WRNMMC consented 4 patients and currently have 2 actively enrolled. Patients not currently in the study were due to one patient being lost to follow-up as he indicated that he will not be returning for the study and the other separated from the military.

The study team at BAMC consented a total of 10 patients and currently have 4 actively enrolled. Patients not currently in the study were due to one patient being lost to follow-up at the 18 month visit, two patients withdrawn due to nerve gaps exceeding 7 cm in length, one patient withdrawn due to not needing the nerve graft, one patient withdrawn due to an infection of the dorsi pedicle myofasciocutaneous flap causing the graft to be removed and one patient passing away due to an unrelated study event.

There were two reported unrelated serious adverse events at BAMC. Patient 009-SAM had an infection at the dorsi pedicle myofasciocutaneous flap causing the graft to be removed. The IRB was notified on October 25, 2018. Patient 005-SAM passed away on April 18, 2019 due to an unrelated study event. The IRB was notified on April 18, 2019.

#### **Impact**

Military combat injuries to the extremities from blast, fragmentary, and ballistic injury can result in a spectrum of musculoskeletal trauma to include injuries to the soft tissues, vessels, nerves, and bone. It has been reported that while body armor has decreased the mortality associated with combat trauma, there is actually an increase in severe traumatic injury to the upper extremity in the surviving warrior. The incidence and prevalence of extremity injury has been on the rise significantly in the 21st century, with 54% of all casualties seen to involve extremity injury in 2006 up from 22% just 3 years prior. Costlier still is the fact that 65% of inpatient care is devoted to such wounds which are known to have the highest long-term costs associated with them – both a drain on military medical resources. The proposed phase I safety study complements the ongoing DoD and VA areas of interest by decreasing the burden of wounded warriors in the short term by lessening length of rehabilitation, and in the long term by reducing recidivistic chronic ailments. Moreover, these wounded service members have often sustained injuries to multiple limbs, often deeming the autograft sites unviable. The recent availability of the only commercially viable peripheral nerve allograft (Avance®, AxoGen Inc.) presents an attractive alternative to harvesting autograft by offering numerous benefits to the patient, including decreased operative time and no donor site morbidity. Furthermore, while the efficacy of these options have already been documented, there are limitations on the expected level of recovery and on the length of discontinuity that can be treated. The addition of a Warriors own BMSC's is expected to further improve outcomes and has shown a long safety record and is a standard point-of-care procedure. This proposed phase I safety trial, has the potential for establishing a safety record for the synergistic effect of the allograft and autologous stem cells leading to the acceleration and translation of advances in knowledge into new treatment algorithms for combat related injuries through evidence-based practices for the peripheral nerve repair.

# **Changes/Problems**

No key personnel changes occurred this past year. A new program manager for this award started in July 2018 and the clinical research nurse relocated to San Antonio, TX. He manages the study team from Bethesda, MD.

# **Products**

No products have been generated to date.

# Participants and Other Collaborating Organizations

WRNMMC, SAMMC and Cleveland Clinic and Curtis National Hand Center are all collaborating on this project. Work at both WRNMMC and SAMMC is managed through HJF directly. The subaward to the Cleveland Clinic is ongoing.

## **Special Reporting Requirements**

None

# **Appendices**

None